<DOC>
	<DOCNO>NCT00183612</DOCNO>
	<brief_summary>This study examine safety effectiveness antipsychotic drug olanzapine child adolescent bipolar disorder psychosis .</brief_summary>
	<brief_title>Determining Safety Effectiveness Olanzapine Children Adolescents</brief_title>
	<detailed_description>Numerous advancement mental health treatment make past decade . Unfortunately , advancement focus adult fully extend child adolescent . With limited pediatric information pharmacokinetics pharmacodynamics drug use treat mental health problem , psychiatrist prescribe drug child use data extrapolate adult , may lead potentially life-threatening result . Olanzapine widely prescribe treat child adult . This study determine safety effectiveness olanzapine child adolescent mental health disorder . The study also compare effect gender , development , body composition , metabolic genotype phenotype olanzapine work . All participant receive olanzapine 8 week . Blood collection occur weekly study visit . On Visit 1 , participant receive first dose olanzapine repeat blood collection occur every hour 24 hour . Blood collection use determine time take olanzapine absorb body , duration action , extent distribution body , manner excrete body , effect organ body .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Diagnosis bipolar disorder mania , mixed mania , psychosis otherwise specify Meet certain laboratory result requirement Have take either lithium valproate 4 week longer partial response Parent guardian willing provide inform consent History serious unstable illness require medication Diabetes mellitus Abnormal physical examination electrocardiogram ( EKG ) result At risk suicide homicide ( base assessment suicidal history , intent plan , mental state , mood , substance use ) IQ le 65 History organic brain disease seizure disorder Recent exposure infectious disease , tuberculosis ( TB ) meningitis Current use drug may interfere metabolism olanzapine unwilling discontinue use study Body mass index ( BMI ) less 5th OR great 95th percentile age gender History smoking within 1 year prior study entry Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Child</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Mental Health</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacology</keyword>
</DOC>